Patents by Inventor Gaowu LIN

Gaowu LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof
    Patent number: 11098123
    Abstract: An OCTS-based CAR-T vector for treating pancreatic cancer and malignant mesothelioma includes lentiviral skeleton plasmid, human EF1? promoter (SEQ ID NO: 14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody; the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO: 15), PDL1 single-chain antibody light chain VL (SEQ ID NO: 16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO: 17), mesothelin single-chain antibody light chain VL (SEQ ID NO: 18), mesothelin single-chain antibody heavy chain VH (SEQ ID NO: 19), antibody Inner-Linker (SEQ ID NO: 20), single-chain antibody Inter-Linker (SEQ ID NO: 21), CD8 Hinge chimeric receptor linker (SEQ ID NO: 22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO: 23), TCR chimeric receptor T cell activation domain (SEQ ID NO: 26) and chimeric receptor co-stimulator domain.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: August 24, 2021
    Assignee: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
    Inventors: Wei Qi, Lei Yu, Liqing Kang, Gaowu Lin, Zhou Yu
  • Malignant glioma CAR-T therapeutic vector based on OCTS technology, and construction method and application thereof
    Patent number: 10934357
    Abstract: An OCTS-based CAR-T vector for treating malignant glioma includes lentiviral skeleton plasmid, human EF1? promoter (SEQ ID NO.14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody; the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), PDL1 single-chain antibody light chain VL (SEQ ID NO.16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO.17), EGFRvIII single-chain antibody light chain VL (SEQ ID NO.18), EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO.19), antibody Inner-Linker (SEQ ID NO.20), single-chain antibody Inter-Linker (SEQ ID NO.21), CD8 Hinge chimeric receptor linker (SEQ ID NO.22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and chimeric receptor co-stimulator domain.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: March 2, 2021
    Assignee: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
    Inventors: Wei Qi, Lei Yu, Liqing Kang, Gaowu Lin, Zhou Yu
  • OCTS TECHNOLOGY-BASED PANCREATIC CANCER AND MALIGNANT MESOTHELIOMA CAR-T THERAPEUTIC VECTOR, CONSTRUCTION METHOD THEREFOR, AND USE THEREOF
    Publication number: 20200181269
    Abstract: An OCTS-based CAR-T vector for treating pancreatic cancer and malignant mesothelioma includes lentiviral skeleton plasmid, human EF1? promoter (SEQ ID NO.14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody; the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), PDL1 single-chain antibody light chain VL (SEQ ID NO.16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO.17), MESOTHELIN single-chain antibody light chain VL (SEQ ID NO.18), MESOTHELIN single-chain antibody heavy chain VH (SEQ ID NO.19), antibody Inner-Linker (SEQ ID NO.20), single-chain antibody Inter-Linker (SEQ ID NO.21), CD8 Hinge chimeric receptor linker (SEQ ID NO.22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and chimeric receptor co-stimulator domain.
    Type: Application
    Filed: November 13, 2017
    Publication date: June 11, 2020
    Applicant: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
    Inventors: Wei QI, Lei YU, Liqing KANG, Gaowu LIN, Zhou YU
  • MALIGNANT GLIOMA CAR-T THERAPEUTIC VECTOR BASED ON OCTS TECHNOLOGY, AND CONSTRUCTION METHOD AND APPLICATION THEREOF
    Publication number: 20200181268
    Abstract: An OCTS-based CAR-T vector for treating malignant glioma includes lentiviral skeleton plasmid, human EF1? promoter (SEQ ID NO.14), OCTS chimeric receptor structural domain, and PDL1 single-chain antibody; the OCTS chimeric receptor structural domain consists of CD8 leader chimeric receptor signal peptide (SEQ ID NO.15), PDL1 single-chain antibody light chain VL (SEQ ID NO.16), PDL1 single-chain antibody heavy chain VH (SEQ ID NO.17), EGFRvIII single-chain antibody light chain VL (SEQ ID NO.18), EGFRvIII single-chain antibody heavy chain VH (SEQ ID NO.19), antibody Inner-Linker (SEQ ID NO.20), single-chain antibody Inter-Linker (SEQ ID NO.21), CD8 Hinge chimeric receptor linker (SEQ ID NO.22), CD8 Transmembrane chimeric receptor transmembrane domain (SEQ ID NO.23), TCR chimeric receptor T cell activation domain (SEQ ID NO.26) and chimeric receptor co-stimulator domain.
    Type: Application
    Filed: November 13, 2017
    Publication date: June 11, 2020
    Applicant: SHANGHAI UNICAR-THERAPY BIO-MEDICINE TECHNOLOGY CO., LTD
    Inventors: Wei QI, Lei YU, Liqing KANG, Gaowu LIN, Zhou YU